Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux

Yasuhisa Izushi, Yoichiro Takami, Naofumi Shiota, Tomonori Tetsunaga, Yusuke Ookura, Kenichi Shimada, Takashi Egawa, Tsukasa Kiuchi, Toru Sato, Ritsugi Takuma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban 30 mg compared with fondaparinux 2.5 mg in TKA patients. Two hundred twenty nine patients who underwent TKA in National Hospital Organization Okayama Medical Center from July 2010 to June 2012 were divided into two groups; pre and post approval of edoxaban: fondaparinuxgroup (F-group) and edoxaban-group (E-group). As the primary endpoint, the frequency of postoperative anemia was evaluated. Blood coagulation values and relations between these parameters and postoperative anemia were also investigated. The frequency of postoperative anemia was significantly higher in E-group than F-group patients (52.7% vs. 37.8%; p

Original languageEnglish
Pages (from-to)516-523
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume39
Issue number4
Publication statusPublished - Apr 1 2016

Fingerprint

Knee Replacement Arthroplasties
Anemia
Blood Coagulation
Anticoagulants
Oral Administration
edoxaban
fondaparinux

Keywords

  • Edoxaban
  • Postoperative Anemia
  • Prothrombin Time
  • Total Knee Arthroplasty

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux. / Izushi, Yasuhisa; Takami, Yoichiro; Shiota, Naofumi; Tetsunaga, Tomonori; Ookura, Yusuke; Shimada, Kenichi; Egawa, Takashi; Kiuchi, Tsukasa; Sato, Toru; Takuma, Ritsugi.

In: Biological and Pharmaceutical Bulletin, Vol. 39, No. 4, 01.04.2016, p. 516-523.

Research output: Contribution to journalArticle

Izushi, Y, Takami, Y, Shiota, N, Tetsunaga, T, Ookura, Y, Shimada, K, Egawa, T, Kiuchi, T, Sato, T & Takuma, R 2016, 'Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux', Biological and Pharmaceutical Bulletin, vol. 39, no. 4, pp. 516-523.
Izushi, Yasuhisa ; Takami, Yoichiro ; Shiota, Naofumi ; Tetsunaga, Tomonori ; Ookura, Yusuke ; Shimada, Kenichi ; Egawa, Takashi ; Kiuchi, Tsukasa ; Sato, Toru ; Takuma, Ritsugi. / Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux. In: Biological and Pharmaceutical Bulletin. 2016 ; Vol. 39, No. 4. pp. 516-523.
@article{592ca6903b084380bbf4492238420aae,
title = "Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux",
abstract = "Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban 30 mg compared with fondaparinux 2.5 mg in TKA patients. Two hundred twenty nine patients who underwent TKA in National Hospital Organization Okayama Medical Center from July 2010 to June 2012 were divided into two groups; pre and post approval of edoxaban: fondaparinuxgroup (F-group) and edoxaban-group (E-group). As the primary endpoint, the frequency of postoperative anemia was evaluated. Blood coagulation values and relations between these parameters and postoperative anemia were also investigated. The frequency of postoperative anemia was significantly higher in E-group than F-group patients (52.7{\%} vs. 37.8{\%}; p",
keywords = "Edoxaban, Postoperative Anemia, Prothrombin Time, Total Knee Arthroplasty",
author = "Yasuhisa Izushi and Yoichiro Takami and Naofumi Shiota and Tomonori Tetsunaga and Yusuke Ookura and Kenichi Shimada and Takashi Egawa and Tsukasa Kiuchi and Toru Sato and Ritsugi Takuma",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "39",
pages = "516--523",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux

AU - Izushi, Yasuhisa

AU - Takami, Yoichiro

AU - Shiota, Naofumi

AU - Tetsunaga, Tomonori

AU - Ookura, Yusuke

AU - Shimada, Kenichi

AU - Egawa, Takashi

AU - Kiuchi, Tsukasa

AU - Sato, Toru

AU - Takuma, Ritsugi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban 30 mg compared with fondaparinux 2.5 mg in TKA patients. Two hundred twenty nine patients who underwent TKA in National Hospital Organization Okayama Medical Center from July 2010 to June 2012 were divided into two groups; pre and post approval of edoxaban: fondaparinuxgroup (F-group) and edoxaban-group (E-group). As the primary endpoint, the frequency of postoperative anemia was evaluated. Blood coagulation values and relations between these parameters and postoperative anemia were also investigated. The frequency of postoperative anemia was significantly higher in E-group than F-group patients (52.7% vs. 37.8%; p

AB - Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban 30 mg compared with fondaparinux 2.5 mg in TKA patients. Two hundred twenty nine patients who underwent TKA in National Hospital Organization Okayama Medical Center from July 2010 to June 2012 were divided into two groups; pre and post approval of edoxaban: fondaparinuxgroup (F-group) and edoxaban-group (E-group). As the primary endpoint, the frequency of postoperative anemia was evaluated. Blood coagulation values and relations between these parameters and postoperative anemia were also investigated. The frequency of postoperative anemia was significantly higher in E-group than F-group patients (52.7% vs. 37.8%; p

KW - Edoxaban

KW - Postoperative Anemia

KW - Prothrombin Time

KW - Total Knee Arthroplasty

UR - http://www.scopus.com/inward/record.url?scp=84964620245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964620245&partnerID=8YFLogxK

M3 - Article

C2 - 27040624

AN - SCOPUS:84964620245

VL - 39

SP - 516

EP - 523

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -